There are few more moving moments, if any, than seeing someone whose bandages have been removed after eye surgery who is able to see again after the near loss of sight. The Cornea Research Foundation of America believes this and for that reason established the mission to be a world class research and educational organization, dedicated to the preservation and restoration of vision. We work to “give people back the use of their eyes.”
Your Kind Support
Donations to the Cornea Research Foundation of America, a 501(c)3 tax exempt organization (TIN 31-1243592) are tax-deductible and help restore hope and sight to people from all walks of life. Contributions allow research to continue identifying the causes of disabling conditions such as Fuchs’ Dystropy and keratoconus, so that future generations can enjoy better vision. If you would like to make a gift to the Foundation, you may make a gift online or send your gift to the Cornea Research Foundation at 9002 N. Meridian Suite 212 Indianapolis, IN 46260.
The Cornea Research Foundation of America (CRFA) was founded by Francis W. Price Jr., M.D. in 1988 with a mission to establish a world center for clinical research and education specializing in corneal disease, corneal transplantation and intraocular lens surgery. A visionary physician, Dr. Price understood that corneal surgeries were increasing, in part, due to complications following cataract surgeries. In response, he created a database to store and track preoperative, surgical and postoperative statistics for transplants performed since 1982 within Price Vision Group.
His efforts were strengthened when the Indiana Lions Bank became involved with the Foundation in 1990. Their contributions and many generous supporters have helped maintain the burgeoning information database that now houses data more than 5,000 transplants. Although the Foundation’s primary focus is on transplant data, its mission has evolved to include many other vision research initiatives.
In 1991, the Foundation began participating in FDA Investigational Studies* involving the use of the excimer laser. While previous studies sponsored by excimer manufacturers focused on gaining marketing approval for lasers, Price Vision Group was granted approval for three of its own Investigational Device Exemption (IDE) studies to evaluate the LASIK (laser-assisted in situ keratomileuisis) procedure using the excimer laser. These studies centered on improved patient safety, various therapeutic means to improve visual results, and the effect of age, gender and smoking on visual results, areas that laser manufacturers would not have pursued or funded.
Patient consent is obtained for studies using human subjects. All prospective studies are done with Institutional Review Board approval and in accordance with applicable National Institute of Health and Federal Drug Administration guidelines.
Since its inception, the Foundation has been led by Dr. Price’s passion for innovation, lifelong learning and, to date, CRFA has participated in 80 clinical and investigational studies and published over 100 papers and manuscripts (see Publications link on this site). The Foundation also holds regular seminars and courses for physicians, as well as patients, regarding developments in ophthalmology. Visionary, a newsletter published by the Foundation four times a year, is disseminated to patients, ophthalmologists and optometrists.
These contributions have earned the Foundation an international reputation as a leader in ophthalmic research.
* FDA Investigational Studies are carried out on either drugs or devices prior to their approval for sale.